CCME Global

Which are the latest news on CCME Global?

Why is Genesis IBRC India Ltd falling/rising?

As of 26-Jun, CCME Global Ltd's stock price is at 125.00, down 1.0 (-0.79%), following a trend reversal after three days of gains. Despite this decline, the stock has performed well overall, with a 10.38% increase in the past week and a 46.54% rise year-to-date, while trading above key moving averages and seeing increased investor participation.

As of 26-Jun, CCME Global Ltd's stock price is currently at 125.00, reflecting a decrease of 1.0 (-0.79%). The stock has experienced a trend reversal, having fallen after three consecutive days of gains. Despite this recent decline, the stock has shown strong performance over various periods, including a 10.38% increase over the past week and a remarkable 46.54% rise year-to-date. <BR><BR>Additionally, the stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a generally positive trend over the longer term. However, the broader sector, specifically the Plastic Products sector, has seen a decline of 2.18%, which may be influencing the stock's current performance. <BR><BR>Investor participation appears to be increasing, as evidenced by a significant rise in delivery volume, which was up by 202.96% compared to the 5-day average. This suggests that while the stock is currently experiencing a minor decline, the overall trend and investor interest remain strong.

How big is CCME Global?

As of 10th June, CCME Global Ltd has a market capitalization of 431.00 Cr, with recent net sales of 0.04 Cr and a net profit loss of 0.71 Cr. Shareholder's funds are 9.61 Cr, and total assets amount to 12.29 Cr as of March 2018.

As of 10th June, CCME Global Ltd has a market capitalization of 431.00 Cr, classified as a Micro Cap.<BR><BR>In the latest four quarters, CCME Global reported Net Sales of 0.04 Cr and a Net Profit loss of 0.71 Cr.<BR><BR>The latest annual period for the balance sheet is March 2018, with Shareholder's Funds amounting to 9.61 Cr and Total Assets of 12.29 Cr.

Who are in the management team of CCME Global?

The management team of CCME Global includes Vanitha Nagulavari (Director), Mohammed Baba (Independent Director), Prasada Rao Kalluri (Independent Director), Balakrishna Koppula (Whole-time Director), and M V R L Subrahmanyeswara Rao (Company Secretary & Compliance Officer).

The management team of CCME Global includes the following individuals:<BR><BR>1. **Vanitha Nagulavari** - Director<BR>2. **Mohammed Baba** - Independent Director<BR>3. **Prasada Rao Kalluri** - Independent Director<BR>4. **Balakrishna Koppula** - Whole-time Director<BR>5. **M V R L Subrahmanyeswara Rao** - Company Secretary & Compliance Officer<BR><BR>If you have any more questions about CCME Global or its management, feel free to ask!

Who are the peers of the CCME Global?

CCME Global's peers include Kilitch Drugs, Zim Laboratories, Amanta Healthcare, Jenburkt Pharma, Bafna Pharma, Haleos Labs, Albert David, Valiant Laborato, and Influx Health. CCME Global has a 1-year return of 348.05%, significantly outperforming its peers, with Bafna Pharma having the highest return at 135.40% and Valiant Laborato the lowest at -40.70%.

Peers: The peers of CCME Global are Kilitch Drugs, Zim Laboratories, Amanta Healthcar, Jenburkt Pharma, Bafna Pharma, Haleos Labs Limi, Albert David, Valiant Laborato, and Influx Health.<BR><BR>Quality Snapshot: Excellent management risk is observed at Jenburkt Pharma, while Average management risk is found at Zim Laboratories, Haleos Labs Limi, Albert David, and Influx Health. Below Average management risk is noted for Kilitch Drugs, Amanta Healthcar, Bafna Pharma, CCME Global, and Valiant Laborato. In terms of Growth, Excellent growth is seen at Kilitch Drugs, while Average growth is found at Zim Laboratories, Influx Health, and the rest. Below Average growth is noted for Amanta Healthcar, Jenburkt Pharma, Bafna Pharma, Haleos Labs Limi, CCME Global, Albert David, and Valiant Laborato. For Capital Structure, Excellent capital structure is observed at Jenburkt Pharma, Albert David, and Influx Health, while Good capital structure is noted for Kilitch Drugs and CCME Global, and the rest have Below Average or Average ratings.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Bafna Pharma at 135.40%, while the peer with the lowest is Valiant Laborato at -40.70%. CCME Global's 1-year return of 348.05% is significantly higher than all peers. Additionally, Haleos Labs Limi, Albert David, and Valiant Laborato have negative six-month returns.

What does CCME Global do?

CCME Global Ltd operates in the Pharmaceuticals & Biotechnology industry as a Micro Cap company, reporting net sales and profit of 0 Cr for March 2026, with a market cap of INR 431 Cr. The company has undergone several name changes since its incorporation in 1992.

Overview:<BR>CCME Global Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated as Fine Plast Polymers Ltd in October 1992, later changing its name to SSK Lifestyles Ltd in October 2014, and finally to Genesis IBRC India Ltd in January 2018. The latest quarterly results report net sales and net profit of 0 Cr for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 431 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 36 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.93 <BR>Return on Equity: -1.77% <BR>Price to Book: 10.76<BR><BR>Contact Details:<BR>Address: Sy Nos 241/2 & 389/2 Dwaraka, Denduluru Village & Mandal West Godavari Andhra Pradesh : 534432 <BR>Email: info@ssklifstyles.com <BR>Website: http://www.genesisbrc.com

Should I buy, sell or hold Genesis IBRC India Ltd?

When is the next results date for Genesis IBRC India Ltd?

The next results date for Genesis IBRC India Ltd is 14 February 2026.

The next results date for Genesis IBRC India Ltd is scheduled for 14 February 2026.

How has been the historical performance of Genesis IBRC?

Genesis IBRC reported a total operating income of 4.34 Cr for the year ending March 2018, resulting in a profit after tax of -0.03 Cr and an earnings per share of -0.03. The company had total liabilities and assets of 12.29 Cr, with no cash flow activity during the period.

Answer:<BR>The historical performance of Genesis IBRC for the year ending March 2018 shows a total operating income of 4.34 Cr, with net sales contributing 4.33 Cr. The total expenditure, excluding depreciation, was 4.16 Cr, leading to an operating profit (PBDIT) of 0.18 Cr. After accounting for interest expenses of 0.03 Cr and depreciation of 0.09 Cr, the profit before tax was recorded at 0.06 Cr. However, the company faced a tax expense of 0.10 Cr, resulting in a profit after tax of -0.03 Cr, which also reflects in the consolidated net profit. The earnings per share (EPS) stood at -0.03, indicating a loss per share. The operating profit margin was 4.2%, while the profit after tax margin was -0.78%. The company had a total liability of 12.29 Cr, with shareholder's funds amounting to 9.61 Cr and total assets also at 12.29 Cr. The cash flow results indicated no cash inflow or outflow during the period.<BR><BR>Breakdown:<BR>Genesis IBRC's financial results for March 2018 reveal a total operating income of 4.34 Cr, primarily driven by net sales of 4.33 Cr. The company managed to maintain a low total expenditure of 4.16 Cr, resulting in an operating profit of 0.18 Cr. However, the profit before tax was only 0.06 Cr, which turned negative after accounting for tax expenses, leading to a profit after tax of -0.03 Cr. This loss per share is reflected in the earnings per share of -0.03. The company's operating profit margin was 4.2%, but the profit after tax margin was negative at -0.78%. On the balance sheet, total liabilities matched total assets at 12.29 Cr, with shareholder's funds at 9.61 Cr. The cash flow statement indicated no activity, with a closing cash balance of 0.00 Cr.

Is Genesis IBRC overvalued or undervalued?

As of September 5, 2025, Genesis IBRC is considered very expensive and overvalued, with high valuation ratios compared to peers and a PEG ratio of 0.00 indicating no expected growth, despite a strong historical return of 281.47% over three years.

As of 5 September 2025, the valuation grade for Genesis IBRC has moved from risky to very expensive, indicating a significant shift in its perceived value. The company is currently considered overvalued. Key ratios reveal a PE ratio of 14.83, an EV to EBITDA of 14.79, and a Price to Book Value of 10.33, which are notably high compared to industry peers.<BR><BR>In comparison to its peers, Genesis IBRC's valuation metrics are considerably less favorable. For instance, Supreme Industries has a PE ratio of 65.23, while Astral's PE stands at 80.78, both indicating a premium valuation. Additionally, the PEG ratio for Genesis is reported at 0.00, which suggests no expected growth, further reinforcing the overvaluation stance. Despite a strong performance with a 281.47% return over three years, the current valuation metrics suggest that investors should approach Genesis IBRC with caution.

Who are the top shareholders of the Genesis IBRC?

The top shareholders of Genesis IBRC are Diligent Industries Limited with 23.08%, and promoter Arun Kumar P with 4.49%. Individual investors collectively hold 49.31% of the shares, with no institutional or pledged promoter holdings reported.

The top shareholders of Genesis IBRC include Diligent Industries Limited, which holds the highest public shareholding at 23.08%. Additionally, Arun Kumar P is the promoter with the highest individual holding at 4.49%. Individual investors collectively hold 49.31% of the shares. There are no institutional holdings or pledged promoter holdings reported.